WeedMD Inc (WMD)

[bsdelectro]

I have been keeping tabs on WMD news and am encouraged with the Alberta gaming agreement and the shoppers drug mart deal.... looking good. What I don't get is no trading volume and no Ihub discussion. Echo echo echo... anybody here?

Their social media skills are horrible too. No buzz created. I am a little concerned in my position.

[JMoriarty]

Trusting the process from genetic clone to consumer sale is everything. BlockStrain is absolutely necessary for 'verifying' product


Anytime friends come by.. i ask, do u trust this doesn't have anything.. it's always the 'reputation' of the person versus product


I want to scan the product.. see where it comes from and then consume.


Suite should launch in a few short weeks according to the CEO.

[bsdelectro]

I invested in WMD and can't believe I got it at such a low price. This stock is going to double in no time. The management and direction of this company is brilliant. This is going to be a crazy ride. I just wish I had more money to invest.

[User-65225]

Nice investment in BKKSF: Canada: a Blockchain Testing Ground for Cannabis Cultivators
By David Bentley -June 22, 2018

https://www.the-blockchain.com/2018/06/22/canada-a-blockchain-testing-ground-for-cannabis-cultivators/

A recent report by global consulting firm Deloitte on how blockchain technology can revolutionize the retail and consumer goods industries is being hailed by — the now legal –Canadian cannabis sector as an area of major growth for supply chain Track and Trace systems.

Deloitte’s report, titled “New Tech on the Block: Planning for Blockchain in the Retail and Consumer Goods Industries”, was highlighted by North American cannabis industry network CFN Media Group, in an article on TSX Venture exchange-listed Blockstrain Technology Corp, which has developed a blockchain-based system to streamline genetic and quality control testing of cannabis products, to track cannabis from “gene to sale.”

“We expect a tipping point within the next five years, as businesses begin to appreciate blockchains’ ability to track and trace products, record contracts and transactions, and guarantee the movement of information,” said Dr. Bryn Walton and Ben Perkins, the authors of Deloitte’s report. “The result will be widespread adoption of blockchain following a period of trials and pilots.”

According to CFN Media, Canada’s newly legalized cannabis industry is seen as the perfect testing ground for blockchain supply chain solutions. Canada has created a very strict and robust regulatory process to ensure that consumers receive high-quality products that aren’t tainted and deliver the promised mix of cannabinoids. However, these strict processes can be a high bar for cultivators, distributors, and retailers to meet with their limited resources. At the same time, the producers themselves are inventing how the industry works each day. For example, producers are breeding thousands of new cannabis strains, but there are no procedures in place to verify who owns those strains or how they can be used by other cultivators.

“When you deal with this strictly controlled substance, governments want to know where those shipments are; they want to know the product has been tested and is safe for the consumers; and, they want to make sure there is no diversion to the black market, which has been an issue in jurisdictions outside Canada,” said Blockstrain CTO Tommy Stephenson in the CFN Media statement.

Licensed Canadian producer WeedMD has already adopted Blockstrain’s system and the management team has invested USD 500,000 into its parent company. CFO Keith Merker said he believes that the key value is protecting WeedMD’s intellectual property as it develops new strains that could each be worth millions of dollars.

“Unique and differentiated strains and product offerings have always been, and will remain, a cornerstone of WeedMD’s business model,” Merker said in the statement. “Validating and protecting that intellectual property through BlockStrain’s platform will prove invaluable as we scale operations and broaden our distribution throughout the country, as well as internationally.”

[TrendTrade2016]

WMD.V nice gapper

[TrendTrade2016]

WMD.V monster weeder about to blast off!!!

[Cheetah SPEED]

HALTED

[excboe]

WMD up 30% and Hiku down 30%. Looks like Hiku stock holders got shafted by the deal and the market is showing it.

[MisterEnzo]

Wowza

[UnderOath-KY]

Just announced

[DoubleJackie]

Why did this pop when Hiku tumbled. MERGE happening

[UnderOath-KY]

Tomorrow has arrived !

[UnderOath-KY]

somebody taken this down hard, but better days ahead!!!

[UnderOath-KY]

WeedMD Completes Strategic Investment in Blockstrain Technology Corp.
Articles, Press Release

Toronto, Canada, March 19, 2018 – WeedMD Inc. (TSX-V:WMD) (OTC:WDDMF) (FSE:4WE) (“WeedMD” or the “Company”), a Licensed Producer under Health Canada’s Access to Cannabis for Medical Purposes Regulations (“ACMPR”), is pleased to announce that it has made a strategic investment in Scorpion Resources Inc., to be renamed Blockstrain Technology Corp. (TSX-V:SR.H) (“Blockstrain”). WeedMD will be amongst the first federally-licensed producers to initiate the integration of blockchain technology into its ecosystem. Blockstrain delivers a secure and immutable blockchain platform to establish global certainty for cannabis strains and their ownership.

Blockstrain has developed a comprehensive cannabis genetics archiving platform. The platform aims to transform the way global cannabis business transactions and operations are conducted by providing an incorruptible environment that automates, accelerates and encodes transactions while ensuring privacy and security for all involved parties.

“WeedMD has amongst the most robust and expansive library of genetics in the industry. After conducting an extensive review of the blockchain technologies being proposed for and utilized in the cannabis sector, we believe that Blockstrain is best positioned to protect our intellectual property by further validating and securing our best-in-class genetics,” said Derek Pedro, Design, Cultivation and Production Partner at WeedMD. “Our strategic partnership with Blockstrain will position and benefit WeedMD as we obtain and develop new strains to expand our wholesale genetics business and for the benefit of our medical patients.”

“We are thrilled to have the strategic support of WeedMD in the development and launch of our technology-based solutions,” said Robert Galarza, CEO of Blockstrain. “Our platform brings the best aspects of blockchain technology into the cannabis industry in order to protect the intellectual property of producers, while giving customers visibility and transparency. By utilizing Blockstrain, WeedMD can now expand its library of world class genetics while building customers’ trust in the quality of the products they are purchasing.”

Under the terms of the strategic investment agreement WeedMD has invested $500,000 into Scorpion Resources, Inc., who has entered in to an agreement to acquire Blockstrain, which will serve as its Qualifying Transaction. Upon completion of the Qualifying Transaction, Michael Kraft, Chairman of WeedMD, will be appointed as a director of Blockstrain.

About WeedMD Inc.:

WeedMD Inc. is the publicly-traded parent company of WeedMD Rx Inc., a federally-licensed producer and distributor of medical cannabis and oils under the Access to Cannabis for Medical Purposes Regulations (ACMPR). The Company operates a 26,000 sq. ft. indoor facility in Aylmer, Ontario, and is awaiting its second-site cultivation license for its greenhouse facility located in Strathroy, Ontario, representing 610,000 sq. ft. or 14 acres under glass. WeedMD has entered into supply agreements in addition to strategic relationships with established cannabis brands. The Company is focused on providing medical cannabis to the seniors’ markets in Canada through its proprietary seniors care program. It is dedicated to educating healthcare practitioners and furthering public understanding of the role that medical cannabis plays – including as it pertains to regulatory requirements, indications and potential side effects.

For more information, access our investor presentation here and corporate video here.

About Blockstrain Technology Corp.

Blockstrain is developing a comprehensive, community-driven cannabis genetics registration and licensing archive platform, dedicated to making it safe and conformable for breeders and growers, large and small, to protect and release their varieties into the public domain, while also being compensated and rewarded. Blockstrain has accomplished this by utilizing blockchain and cryptocurrency features to create an ecosystem that encourages contribution of genetics and intellectual property, coupled with the security, authenticity and verification methods that modern distributed ledger technology provides.

Blockstrain combines traditional cannabis culture with modern crypto-technology to deliver a truly intelligent platform powered by the people. By being open and available to everyone, the platform is expected to help shape the future adoption and authenticity of the cannabis industry. Through use of a secure API network, Blockstrain makes it easy for testing providers, grow facilities, app and software developers, research groups and major supply chain platforms to build applications and solutions, thereby helping fuel technology and innovation for the cannabis industry as a whole.

Follow WeedMD On:



For further information, please contact:

WeedMD Inc.

Keith Merker, Chief Financial Officer
Tel: [phone] Ext. 222
Email: [e-mail]
To learn more, visit us at www.weedmd.com

[UnderOath-KY]

WeedMD Provides Production Update on its 610,000 Square Foot Greenhouse Expansion
Construction on Track and on Budget with First Harvest Expected in July 2018
Print
March 13, 2018 07:35 ET | Source: WeedMD Rx Inc.

TORONTO, March 13, 2018 (GLOBE NEWSWIRE) -- WeedMD Inc. (TSX-V:WMD) (OTC:WDDMF) (FSE:4WE) (“WeedMD” or the “Company”), a federally-licensed producer and distributor of medical cannabis under the Access to Cannabis for Medical Purposes Regulations (“ACMPR”), is pleased to provide an update on its expansion, including the construction and retrofitting of its state-of-the-art 14-acre greenhouse facility in Strathroy, Ontario.

The first phase of construction covers 220,000 sq. ft. of the 610,000 sq. ft. greenhouse and is well underway. Upon completion of security installations and Health Canada site audit, WeedMD anticipates planting its first crop over the next month. With Phase I nearing completion and its first harvest expected in July 2018, WeedMD’s annual production will increase from 1,500 kg to more than 21,000 kg.

With Phase II of the expansion, the Company will begin to retrofit another 175,000 sq. ft. of greenhouse space, which will result in additional annual production of 12,000 kg. This will increase the production area to a total of 395,000 sq. ft. and the Company’s annual production to more than 33,000 kg.

WeedMD’s Greenhouse Expansion

The Company’s expansion into its large-scale modern greenhouse will be the main supply source for its medical cannabis patients, ongoing wholesale supply to other LPs, and future adult-use consumers across Canada in addition to emerging international markets.

About our state-of-the-art modern greenhouse:

Situated on 98-acres of expandable property with 610,000 sq. ft. or 14 acres of existing greenhouse structure in addition to ancillary buildings
Phase I retrofit of 220,000 sq. ft. tempered glass greenhouse that is less than two years old is nearing completion with 22 individual climate-controlled 10,000 sq. ft. production rooms. This will enable WeedMD to harvest one room every 10-12 days, depending on the strain, on a rotational basis.
Equipped with an on-site unlimited supply of natural clean water
Modern fertigation system runs on full-recirculation loop which provides an accurate, innovative computerized method of monitoring plant nutrients and water. This will ensure that water is recycled and reused and does not leach into the surrounding area and that WeedMD meets its environmental responsibilities
Exhaust from our boilers is scrubbed of CO2, cleaned and then utilized for production providing significant cost savings and ensuring optimal plant growth

With a true-hybrid greenhouse, WeedMD will be able to produce indoor quality cannabis, with maximum efficiency and extremely low costs.

“We are on solid footing with a fully-funded, 15-fold production expansion well underway and I am very pleased that we remain on-track and on budget. Our team is looking forward to our first harvest in July 2018,” said Bruce Dawson-Scully, CEO of WeedMD. “Additionally, we are working hard on patient and seniors’ care outreach and engagement programs in addition to launching our strategy for capturing the adult-use market that is expected to significantly increase demand across Canada.”

WeedMD Exercises Option to Purchase Aylmer Property and Facility

WeedMD is also pleased to announce that it has exercised its option to purchase its original production site in Aylmer. This facility includes four acres of land and the Company’s fully licensed and operational 26,000 sq. ft. of indoor production. In addition, WeedMD has the option to purchase an additional four acres of adjacent land to its existing property. This would bring the total footprint to eight acres and enable WeedMD to expand its indoor operations from 26,000 sq. ft. to more than 220,000 sq. ft.

For more about the expansion, read here and watch the corporate video here.

About WeedMD Inc.

WeedMD Inc. is the publicly-traded parent company of WeedMD Rx Inc., a federally-licensed producer and distributor of medical cannabis and oils under the Access to Cannabis for Medical Purposes Regulations (ACMPR). The Company operates a 26,000 sq. ft. indoor facility in Aylmer, Ontario, and is awaiting its second-site cultivation licence for its greenhouse facility located in Strathroy, Ontario, representing 610,000 sq. ft. or 14 acres under glass. WeedMD has entered into supply agreements in addition to strategic relationships with established cannabis brands.

The Company is focused on providing medical cannabis to the seniors’ markets in Canada through its specialized and comprehensive platform. It is dedicated to educating healthcare practitioners and furthering public understanding of the role that medical cannabis plays - including as it pertains to regulatory requirements, indications and potential side effects.

For more information, access our investor presentation here.

Follow WeedMD On:

Facebook: https://www.facebook.com/weedmd/
LinkedIn: https://www.linkedin.com/company-beta/5020743/
Twitter: https://twitter.com/WeedMD
Instagram: https://www.instagram.com/weedmd/

For further information, please contact:

WeedMD Inc.

Keith Merker, Chief Financial Officer
Tel: [phone] Ext. 222
Email: [e-mail]

To learn more, visit us at www.weedmd.com

[UnderOath-KY]

rsi looking good, its been a long decline since Jan10. Im pretty sure thats when I bought a nice chunk.

[JohnCM]

HIKU owns smoke.

[JohnCM]

MD is a good buy at $2.20. I'll have to check to see if they are still DTC ineligible.

[CaptStockWolf]

http://www.cbc.ca/beta/news/canada/manitoba/retail-cannabis-stores-manitoba-1.4538478

[CaptStockWolf]

https://www.google.ca/amp/s/www.weedmd.com/weedmd-van-der-pop-partnership-announcement/amp/

[CaptStockWolf]

Well I’m Manitoba I believe the government offered 4 producers to sell rec. and weedmd has a contract to supply Tokyo smoke Hiku brands I believe.

[JohnCM]

What does 9 have to do with MD?

[CaptStockWolf]

https://mobile.tmxmoney.com/quote/readnews/?id=7422019061020767&symbol=NINE

[UnderOath-KY]

weedMD

[UnderOath-KY]

thanks, its an ira brokerage account

[JohnCM]

No. There just is not a published ask/bid. I'll take a look at Fidelity's domestic vs international trading and stock quotes.

[UnderOath-KY]

so i punch in wmd into the fidelity trade box. It says ticker not found, so i put wmd.v and it lists weedmd with the current price. When I hit refresh it changes it to wddmf with a price of 2.16 currently. Still says weedmd inc Canadian exchange, its confusing. Did I lose my money since its gray, never traded gray.

[JohnCM]

I have not tried an International trade with Fidelity. You must have entered the Canadian ticker as a OTC ticker and it recognized and changed to OTC.

I can trade on the Canadian exchange $20 commish and 1% conversion fee U.S. to CA $$.

No bid/ask because stock is listed on the OTC grey sheet.

Surprised you were not charged $50

I have to buy thru TDAmeritrade along with Phivida, Doja and WeedMD to avoid $50 fee.

[UnderOath-KY]

Sorry its WDDMF

[UnderOath-KY]

[UnderOath-KY]

When I entered WMD.V into my fidelity account to purchase shares it automatically converted it to WMMDF and filled. When I select WMMDF I see zero bid and ask but also see some low volume. Im still trying to figure it out and any help would be appreciated. Im the proud owner of of a nice chunk in WMMDF and not sure what exactly happened. Its described as WeedMD inc. and the news is the same as WMD.V with a 4.95 transaction charge.

[JohnCM]

Really that's all 6.95, so what would be the down side?

No downside. BUY!!

[Bigman7100xxx]

Really that's all 6.95, so what would be the down side?...just wondering why capital one does not even trade the stock.

So I called them and the analyst did not know what I was asking, no call back yet and that was two days ago.

Maybe new broker is in the offering,

[JohnCM]

CRAP!!!

I primarily use Fidelity as my trading account. I have a small balance with TDAmeritrade as well.

As you may know, if a OTC ticker is not DTC eligible, meaning the trade has to be settled manually in lieu of electronically, Fidelity will charge a $50.00 transaction fee. This is the reason I vacated my DOJA and Phivida positions and avoided trading WeedMD.

TDAmeritrade does not do that. They simply charge the standard $6.95 trading commission, DTC eligible or not!

Damn!

[JohnCM]

Nice move ...

[JohnCM]

US Congress Members Defend CBD

As Reported By MJBizDaily:

In a bold show of support for the hemp industry and CBD, 28 members of Congress are asking a federal appeals court to reject the Drug Enforcement Administration’s argument that cannabidiol is a Schedule 1 drug.
The Congress members filed the brief Thursday in conjunction with a pending lawsuit against the DEA.
The 9th Circuit Court of Appeals is set to hear arguments in the case Feb. 15.
The Congress members – 22 Democrats and six Republicans – argue that the DEA is “blatantly contrary” to the 2014 Farm Bill when it argues that CBD is a marijuana extract and therefore illegal.

“The Farm Bill’s definition of industrial hemp includes any part of the plant, including the flower,” the Congress members argue in the brief.

The members conclude that the federal agency’s rule about CBD was an “abuse of DEA’s administrative procedure and rulemaking authority.”

The lawyer who wrote the brief for the Congress members, Steven Cash, told Marijuana Business Dailythat Congress members took the extraordinary step of weighing in on the lawsuit in hopes of seeing the courts resolve the conflict between the Farm Bill and the DEA’s interpretation on the Controlled Substances Act.

“Apart from arguing about the relative benefits, flaws and dangers of medical marijuana and hemp, it appears we’re going to solve this (conflict) through traditional avenues, the courts,” Cash said.

The DEA said in late 2016 that because CBD cannot be easily extracted from non-flower parts of the cannabis plant, CBD should be considered a controlled substance. The decision brought a hasty lawsuit from the Hemp Industries Association and a CBD business.

A lawyer for the hemp companies says the brief will show judges that Congress understood what it was doing when it authorized hemp production, meaning not just the stalks and seeds but the whole plant.

“Congress has spoken, yet again,” Bob Hoban said in a statement. “The industrial hemp industry has seen exponential growth … and this case represents the most significant challenge the U.S. hemp industry has seen to date.”

As Reported By MJBizDaily

[JohnCM]

VANCOUVER, Jan. 15, 2018 /CNW/ - Liberty Leaf Holdings Ltd. (CSE: LIB, OTCQB: LIBFF and FSE: HN3P) (the "Company" or "Liberty Leaf") is pleased to announce it has received processing approval from The Depository Trust Company ("DTC") of New York, NY, making the Company's shares DTC eligible.

DTC provides depository and book entry services for eligible stocks, as well as a settlement system. This means shares can trade electronically. Electronic clearing speeds up the delivery of stock and cash settlements, thereby accelerating trading for investors. DTC is the world's settlement organization for equities across the USA and in 131 other countries. In the USA, DTC handles some 1.4 million settlement transactions daily, valued at approximately $600 billion.

"Liberty Leaf expects that being DTC eligible will greatly simplify the process of trading our common stock on the OTC marketplace in the United States," says Liberty Leaf CEO, William Rascan. "We hope that will stimulate even greater interest in our company as a major player in the legal cannabis sector."

Besides trading electronically on the OTC marketplace in the United States, Liberty Leaf shares will continue to trade on the Canadian Security Exchange (CSE) and Frankfurt Stock Exchange.

[JohnCM]

WHAT IS DTC ELIGIBILITY?

DTC Eligibility means that a public company’s securities are able to be deposited through DTC. DTC is the largest securities depository in the world and holds over thirty-five trillion dollars worth of securities on deposit. DTC accepts deposits of securities from its participants only, who are usually clearing firms. Most brokers clear stock in-house or hire a clearing firm to do so on their behalf. All movements of securities are made to the participant’s account electronically with book-entry adjustments.

Please Email Us with Your Name, Company Name, Phone, Ticker Symbol and Email address to see if we can help you obtain DTC eligibility or to solve other DTC related issues. We can then provide you with a estimated cost to obtain DTC Eligibility.

If an issuer is not DTC eligible, then its shares cannot be transferred between brokerage accounts electronically, which basically means its shares cannot be traded easily. Major Exchanges such as NYSE and NASDAQ require DTC eligibility. Other Platforms such as the OTC Bulletin Board and the Pink Sheet markets do not. Only a DTC participant can request that DTC make a security eligible.

Most large U.S. broker-dealers and banks are DTC participants. Once an issuer has been approved for trading by FINRA, they must apply to DTC for their initial eligibility to trade. If DTC approves the application they will hold all of the issuer’s free-trading street name shares on deposit. As with a Form 15C-211 submission to FINRA , an issuer cannot make a direct application to DTC for eligibility.

The issuer must have a relationship with a broker-dealer or other financial institution that is a participant and will sponsor the eligibility process. This firm is also known as the “market-maker”. They will carry the initial position in inventory on behalf of their firm.

A current List of DTC Participants

(http://www.dtcc.com/downloads/membership/directories/dtc/alpha.pdf) is available on DTC’s web site. The Issuer must also have a transfer agent such as Securities Transfer Corporation that has completed and has on file with DTC a DTC Operational Arrangements Agent Letter, and must also be a participating in DTC’s FAST (Fast Automated Securities Transfer) program.

It is a well-known fact in the securities industry that DTC retains the right to deny a company the ability to use their depository without providing a reason for the denial. Therefore, the eligibility review process should include a clean presentation of facts and documents that meet DTC’s standards.

Eligibility requirements include that the securities must be; issued in a transaction registered with the U.S. Securities and Exchange Commission (“SEC”) pursuant to the Securities Act of 1933, as amended (the “Securities Act”); or issued in a transaction exempt from registration pursuant to a ’33 Act exemption, that at the time of the request for DTC eligibility no longer involves transfer or ownership restrictions; or eligible for resale pursuant to Rule 144A or Regulation S under the ’33 Act (and must otherwise meet DTC’s eligibility criteria).

Possible Document Requirements for Issuers

Whether at the point of initial offering or when the terms of an already eligible security are amended in a corporate action, DTC’s underwriting department may require the issuer to execute and deliver related documentation including, but not limited to, the following:

an offering document

a completed eligibility questionnaire signed by a Participant
For Book-Entry-Only (“BEO”) securities, in addition to the two documents above, an Issuer must provide a DTC Letter of Representation among the Issuer, its Transfer Agent and DTC. The Letter of Representation may be a blanket letter, which is Issuer specific and covers all securities by that Issuer, or an Issuer letter of Representation which is used for one time only issuances.

Book-Entry-Only (“BEO”) securities are securities for which no physical certificates are made available and all securities are maintained by DTC in a “Cede & Co” account. Transactions are made through the FAST program. Most OTC Issuer securities are not BEO.

DTC may request a rider, which is usually only required for REG S or non-U.S. issuers.

Potential Reasons For Rejection

The following points are potential issues that can hinder DTC approval:
(DTC has accepted issuers with these issues below however, DTC eligibility is granted on a case by case basis.)

The issuer should be an SEC reporting company with no history of late filings.

The issuer should have a minimal history of name changes and/or reverse splits in the last five years prior to the eligibility application.

The issuer should have no persons associated directly or indirectly (stock promoters, lawyers, accountants) with the company that have ever been under investigation by the SEC.

DTC will notify the participant if a legal opinion of counsel will be required. The legal opinion should be written by a licensed securities attorney, in good standing with their bar and engaged in an independent private practice. Opinions of in-house counsel will not be relied upon by DTC.

DTC requires that the securities lawyer writing the opinion NOT be a shareholder of the issuer.

DTC reserves the right to approve counsel whose opinion DTC is being asked to rely.

The issuer should have no record of being involved in a spam campaign, pump and dump scheme or any history of fraudulent activity throughout its corporate history.

Affiliates of the issuer should have no record of unregistered re-sales at any brokerage firm.

[Bigman7100xxx]

Ok I will call them when I get home thanks bro!!!

[JohnCM]

WeedMD Announces Closing of $34.5 Million Bought Deal Equity Financing

January 11, 2018 12:54 ET
Source: WeedMD Rx Inc.

TORONTO, Jan. 11, 2018 (GLOBE NEWSWIRE) -- WeedMD Inc. (TSX-V:WMD) (“WeedMD” or the “Company”), a federally-licensed producer and distributor of medical cannabis, is pleased to announce that it has closed its previously announced short form prospectus offering, including the full exercise of the over-allotment option. As such, a total of 16,046,511 units of the Company ("Units") were sold at a price of $2.15 per Unit (the "Issue Price") for aggregate gross proceeds of $34,500,000 (the "Offering"). The Offering was completed by a syndicate of underwriters including Eight Capital as sole bookrunner and co-lead underwriter with Mackie Research Capital Corporation and including Haywood Securities Inc. (the "Underwriters").

Each Unit consists of one common share of the Company (a “Common Share”) and one-half of one Common Share purchase warrant (each whole warrant a “Warrant”). Each Warrant entitles the holder thereof to purchase one Common Share at an exercise price of $2.90, until January 11, 2020. If, following the closing of the Offering, the volume weighted average price of the Common Shares on the TSX Venture Exchange is equal to or greater than $4.20 for any 20 consecutive trading days, the Company may, upon providing written notice to the holders of Warrants, accelerate the expiry date of the Warrants to the date that is 30 days following the date of such written notice.

As consideration for its services, the Underwriters received a cash commission equal to 6% of the gross proceeds of the Offering. The Company also issued 481,395 compensation options to the Underwriters in an amount equal to 3% of the number of Units issued pursuant to the Offering. Each compensation option is exercisable into one Unit at the Issue Price, until January 11, 2020.

The Company intends to use the net proceeds of the Offering to expand its lease footprint and retrofitting plans and operations at its 14-acre Strathroy Greenhouse, to purchase and further develop its Aylmer Facility, to pursue potential strategic domestic and international opportunities and for working capital and general corporate purposes. For more about the expansion, read here.

The Units were offered and sold by way of a short form prospectus filed in each of the provinces of Canada, excluding Quebec, and offered and sold elsewhere outside of Canada on a private placement basis.

The securities referred to in this news release have not been, nor will they be, registered under the United States Securities Act of 1933, as amended (the “1933 Act”), and may not be offered or sold within the United States or to, or for the account or benefit of, U.S. persons absent registration under the 1933 Act or an applicable exemption from such registration requirements. This news release does not constitute an offer for sale of securities for sale, nor a solicitation for offers to buy any securities. “United States” and “U.S. person” are as defined in Regulation S under the 1933 Act.

About WeedMD Inc.:

WeedMD Inc. is the publicly-traded parent company of WeedMD Rx Inc., a federally-licensed producer and distributor of medical cannabis pursuant to the Access to Cannabis for Medical Purposes Regulations (“ACMPR”). The Company operates a 26,000 sq. ft. indoor facility in Aylmer, ON, and is awaiting its second-site cultivation license for its greenhouse facility located in Strathroy, Ontario, representing 610,000 sq. ft. or 14 acres under glass. WeedMD has entered into supply agreements in addition to strategic relationships with established cannabis brands. The Company is focused on providing medical cannabis to the senior’s market including long-term care and assisted living markets in Canada through its proprietary implementation platform. It is dedicated to educating healthcare practitioners and furthering public understanding of the role that medical cannabis plays - including as it pertains to regulatory requirements, indications and potential side effects.

[JohnCM]

At present my Capital one will not let me trade this stock as they say when I called about buying stock WeedMD they don't trade the stock anymore, because its does not meet Capital one guidelines, and because of the penny stock status.

At one point they, maybe will trade the stock again if the certification is completed whatever that means, I asked about certification they said all the stock they trade has a certification.

I believe Canadian companies need to have a U.S. market maker and for the security to be registered.

If it is, then the security needs to be DTC eligible. If the security is not eligible, the settlement of the trade must be done manually.

Typically to trade, what your brokerage refers to as a "penny stock", you need to sign a risk waiver. Or have this done over the phone.

PLEASE PLEASE leave a message for WeedMD and tell them exactly what you told me.

https://www.weedmd.com/contact-weedmd/

[Bigman7100xxx]

Ontario-based WeedMD Rx (OTC: WDDMF) (TSXV: WMD) is also raising funds. In December 2017, the company entered into a letter of engagement for bought deal equity financing of $15 million. WeedMD intends to use the net proceeds of the funding for working capital, general corporate purposes and to position itself to expand production capacity within its recently announced existing 14-acre greenhouse. WeedMD is the publicly traded parent company of WeedMD Rx Inc., a federally licensed producer and distributor of medical cannabis. The company operates a 26,000-square-foot indoor facility in Aylmer, Ontario, and is awaiting its second-site cultivation license for a greenhouse in Strathroy, Ontario, representing 610,000 square feet, or 14 acres under GLASS

[Bigman7100xxx]

John,

At present my Capital one will not let me trade this stock as they say when I called about buying stock WeedMD they don't trade the stock anymore, because its does not meet Capital one guidelines, and because of the penny stock status.

At one point they, maybe will trade the stock again if the certification is completed whatever that means, I asked about certification they said all the stock they trade has a certification.

Pretty much all I could get out of my brokerage on the stock, sorry, I could not get you more info.

[JohnCM]

Any cannabis seller that does not sell clothing, online, is just plain lazy.

swag. Swag refers to valuable goods, often obtained illegally. ... Generally meaning “loot, booty, or plunder,” swag is the stuff in the bags of exited party-goers and plunderers alike. It can also be a bundle carried by a swagman, an Australian migrant worker or drifter.

[charlie02356]

What is "swag" in this context, and why is it relevant to your question?

[JohnCM]

Hi,

I have asked repeated times about the DTC status of the foreign issue OTC ticker for WeedMD.

If I were to purchase shares of WeedMD WDDMF, Fidelity Investments would charge me $50.00 plus $4.95 for a buy and a sell.

Is there anyone at the company who can give me any guidance, good or bad, in regards to the manual or electronic settling of stock trades?

Thank you,

JohnCM
Cannabis Investor


Dear John,

I hope this email finds you well.

The need for swag has been discussed at length and we are working on a way for this to happen with our current point of sale system.

We will make our clients aware once we have this in place.

If you have any further questions you can call our Client Services Team at 1-844-933-3636 from 8AM to 8PM, Monday to Friday.

Best Regards,

Tina Hurley
Client Service Representative
WeedMD Rx Inc.
519-765-2440 ext. 242
250 Elm St. Aylmer, ON N5H 2M8

[JohnCM]

No comprende. I will continue to pressure WeedMD to change status of WDDMF to DTC eligible

Dear John

Thank you for taking time out of your day to contact Fidelity Investments. I am happy to assist you today!

I reviewed the WDDMF security and I can confirm it is subject to the $50 fee.

[JohnCM]

Thank you! I sent this screen shot to Fidelity. I'll get to the bottom of this.

[charlie02356]

Hi John,

[JohnCM]

Research, can you chime in on the DTC eligible question.